Mitovaryn Frequently Asked Questions

Mitovaryn currently features methylene blue drops and BPC-157 capsules. Formulation, availability, price and purchase options can change, so use the current product pages as the definitive source before ordering.

Mitovaryn publishes product-quality information and laboratory documentation. A useful report should identify the tested sample, lot, laboratory, method, specification, result, units and date. Review the lab-test learning center and match any report to the product and lot you intend to buy.

No. A COA may support identity, assay, purity or results for specified contaminants in the tested sample. It does not establish that a product treats disease, produces a claimed benefit, is appropriate for a particular person or is free from every possible contaminant.

No. The products and educational content are not intended to diagnose, treat, cure or prevent disease. Research findings, mechanisms and customer experiences should not be interpreted as a diagnosis, treatment plan or guarantee of results.

Methylene blue is a synthetic thiazine dye with established medical uses in specific formulations and settings, including an FDA-approved intravenous product for acquired methemoglobinemia. It has also been studied in mitochondrial, neurological and other research contexts, but those studies do not approve or validate every oral consumer claim.

Read the current product label and Mitovaryn usage guide, confirm the concentration and use the supplied measuring device. Do not translate an injectable medical dose, animal study or social-media protocol into an oral regimen. Ask a qualified clinician for individualized advice.

Methylene blue can interact dangerously with serotonergic drugs, including many antidepressants, and the complete interaction picture depends on all medicines and supplements used. Do not combine it with a serotonergic medication or alter prescribed treatment without direct guidance from the treating prescriber or pharmacist.

Extra caution is required for people with G6PD deficiency, pregnancy or breastfeeding, kidney or liver impairment, and anyone using prescription medication. The intravenous prescribing information lists G6PD deficiency as a contraindication and warns about serotonin syndrome, fetal harm and other risks. Oral consumer use is not the approved protocol described by that label.

There is no dependable onset time for general energy, focus, mood or wellness outcomes. Customer impressions are subjective and can be affected by dose, formulation, expectations, other substances and health status. A promised result within minutes or days is not established clinical evidence.

BPC-157 is a synthetic 15-amino-acid peptide investigated mainly in laboratory and animal models. It is often discussed for tissue and gastrointestinal research, but its popular description as a natural “body protection compound” should not be mistaken for proof that an oral product produces therapeutic effects in people.

Definitive benefit has not been established through a robust body of controlled human trials. Preclinical findings can justify further research, but they cannot determine whether BPC-157 heals an injury, treats a gastrointestinal disorder, replaces rehabilitation or improves recovery in a specific person. See Does BPC-157 work? for the evidence hierarchy.

There is no FDA-approved BPC-157 drug for treating injury, pain or gastrointestinal disease. FDA has also identified limited safety information and potential concerns involving immunogenicity, peptide-related impurities and active-ingredient characterization for compounded BPC-157. “Pharmaceutical grade” is not the same as FDA approval.

No well-established daily-use safety profile exists. Limited human evidence cannot reliably define uncommon harms, long-term effects, interactions or risks across medical conditions. Product testing can reduce some quality uncertainty but cannot replace clinical safety data.

Athletes should check the current rules that apply to their sport, competition and jurisdiction before use. Anti-doping status can change, and supplement labels do not guarantee compliance or freedom from contamination. Review the athlete guide and confirm with the governing body or anti-doping organization.

The current shipping policy states that orders are processed within 24–48 hours and that United States orders can generally be expected within 5–10 business days. These are estimates rather than guarantees; destination, carrier conditions, customs and peak periods can affect delivery. Review the current shipping policy.

Use the tracking number provided after shipment on the Track Your Order page. If tracking has not updated after the carrier has had time to scan the parcel, contact Mitovaryn with the order number and tracking details.

Eligibility, timing, return-shipping responsibility, exclusions and refund processing are governed by the current refund policy. Read that policy before purchase and contact support within the stated window if you want to request a return. Do not send a parcel back without following the current instructions.

The current subscription policy says customers can use links in their order-confirmation emails to manage, change or cancel a subscription. A renewal already processed may be subject to the return policy. Review the subscription policy and contact support promptly if the account link is unavailable.

Contact Mitovaryn promptly through the contact page. Include the order number, a clear description and photographs of the product, packaging and shipping label when relevant. Keep the item and packaging until support provides instructions.

Use the Mitovaryn contact page for product, order or policy questions. Include your order number for purchase support, but do not send full payment-card details or other unnecessary sensitive information.